Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Hareth Nahi; Saad Z. Usmani; Maria-Victoria Mateos; Niels W. C. J. van de Donk; Albert Oriol; Torben Plesner; Nibedita Bandyopadhyay; Peter Hellemans; Brenda Tromp; Ivo Nnane; Donna Zemlickis; Ajai Chari; Philippe Moreau

doi:https://doi.org/10.1080/10428194.2022.2148221

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Hareth Nahi, Saad Z. Usmani, Maria-Victoria Mateos, Niels W. C. J. van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	468-472
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	64
Issue number	2
Early online date	2023
DOIs	https://doi.org/10.1080/10428194.2022.2148221
Publication status	Published - 2023

Access to Document

https://doi.org/10.1080/10428194.2022.2148221

Cite this

Nahi, H., Usmani, S. Z., Mateos, M.-V., van de Donk, N. W. C. J., Oriol, A., Plesner, T., Bandyopadhyay, N., Hellemans, P., Tromp, B., Nnane, I., Zemlickis, D., Chari, A., & Moreau, P. (2023). Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia and Lymphoma, 64(2), 468-472. https://doi.org/10.1080/10428194.2022.2148221

@article{8cb53307d1b44594910ebcdc208b64fb,

title = "Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study",

author = "Hareth Nahi and Usmani, {Saad Z.} and Maria-Victoria Mateos and {van de Donk}, {Niels W. C. J.} and Albert Oriol and Torben Plesner and Nibedita Bandyopadhyay and Peter Hellemans and Brenda Tromp and Ivo Nnane and Donna Zemlickis and Ajai Chari and Philippe Moreau",

note = "Funding Information: This study was sponsored by Janssen Research & Development, LLC [ClinicalTrials.gov Identifier: NCT02519452]. Medical writing and editorial support were provided by Austin Horton, PhD, and Kristin Runkle, PhD, of Lumanity Communications Inc., and were funded by Janssen Global Services, LLC. The authors would like to acknowledge the patients participating in this study and their families, the staff members at the study sites, the data and safety monitoring committees, and the staff members who were involved in data collection and analyses.",

year = "2023",

doi = "https://doi.org/10.1080/10428194.2022.2148221",

language = "English",

volume = "64",

pages = "468--472",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "2",

}

Nahi, H, Usmani, SZ, Mateos, M-V, van de Donk, NWCJ, Oriol, A, Plesner, T, Bandyopadhyay, N, Hellemans, P, Tromp, B, Nnane, I, Zemlickis, D, Chari, A & Moreau, P 2023, 'Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study', Leukemia and Lymphoma, vol. 64, no. 2, pp. 468-472. https://doi.org/10.1080/10428194.2022.2148221

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. / Nahi, Hareth; Usmani, Saad Z.; Mateos, Maria-Victoria et al.
In: Leukemia and Lymphoma, Vol. 64, No. 2, 2023, p. 468-472.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab

T2 - part 3 of the open-label, multicenter, phase 1b PAVO study

AU - Nahi, Hareth

AU - Usmani, Saad Z.

AU - Mateos, Maria-Victoria

AU - van de Donk, Niels W. C. J.

AU - Oriol, Albert

AU - Plesner, Torben

AU - Bandyopadhyay, Nibedita

AU - Hellemans, Peter

AU - Tromp, Brenda

AU - Nnane, Ivo

AU - Zemlickis, Donna

AU - Chari, Ajai

AU - Moreau, Philippe

N1 - Funding Information: This study was sponsored by Janssen Research & Development, LLC [ClinicalTrials.gov Identifier: NCT02519452]. Medical writing and editorial support were provided by Austin Horton, PhD, and Kristin Runkle, PhD, of Lumanity Communications Inc., and were funded by Janssen Global Services, LLC. The authors would like to acknowledge the patients participating in this study and their families, the staff members at the study sites, the data and safety monitoring committees, and the staff members who were involved in data collection and analyses.

PY - 2023

Y1 - 2023

UR - http://www.scopus.com/inward/record.url?scp=85145504293&partnerID=8YFLogxK

U2 - https://doi.org/10.1080/10428194.2022.2148221

DO - https://doi.org/10.1080/10428194.2022.2148221

M3 - Letter

C2 - 36593729

SN - 1042-8194

VL - 64

SP - 468

EP - 472

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 2

ER -

Nahi H, Usmani SZ, Mateos MV, van de Donk NWCJ, Oriol A, Plesner T et al. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia and Lymphoma. 2023;64(2):468-472. Epub 2023. doi: https://doi.org/10.1080/10428194.2022.2148221

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Access to Document

Other files and links

Cite this